Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria - Wikidata - awgldk - TriplyDB

Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q34328743

about

Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis Expanding the antimalarial toolkit: Targeting host-parasite interactions Absence of apolipoprotein E protects mice from cerebral malaria Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria Toxoplasma gondii upregulates interleukin-12 to prevent Plasmodium berghei-induced experimental cerebral malaria.Chickens treated with a nitric oxide inhibitor became more resistant to Plasmodium gallinaceum infection due to reduced anemia, thrombocytopenia and inflammation.Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion.Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain High plasma erythropoietin levels are associated with prolonged coma duration and increased mortality in children with cerebral malaria.The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria.PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial.Reduced CD36-dependent tissue sequestration of Plasmodium-infected erythrocytes is detrimental to malaria parasite growth in vivo.A novel carbon monoxide-releasing molecule fully protects mice from severe malaria Macrophage migration inhibitory factor in protozoan infections.Laboratory evidence of disseminated intravascular coagulation is associated with a fatal outcome in children with cerebral malaria despite an absence of clinically evident thrombosis or bleeding.Methemoglobin and nitric oxide therapy in Ugandan children hospitalized for febrile illness: results from a prospective cohort study and randomized double-blind placebo-controlled trial.Cytoadherence and severe malaria.Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches.Effect of vitamin A adjunct therapy for cerebral malaria in children admitted to Mulago hospital: a randomized controlled trial.Evaluation of Senna singueana leaf extract as an alternative or adjuvant therapy for malaria.Immunomodulation in Plasmodium falciparum malaria: experiments in nature and their conflicting implications for potential therapeutic agents.Comparison of parasite sequestration in uncomplicated and severe childhood Plasmodium falciparum malaria.Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria.Cytoadherence of Plasmodium berghei-infected red blood cells to murine brain and lung microvascular endothelial cells in vitro.Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?Neuregulin-1 attenuates mortality associated with experimental cerebral malaria.Protective or pathogenic effects of vascular endothelial growth factor (VEGF) as potential biomarker in cerebral malaria.Therapy of vector-borne protozoan infections in nonendemic settings.Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria.HDAC inhibitors in parasitic diseases.Parasitoses of the human central nervous system.Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity?Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.The immunological balance between host and parasite in malaria.Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes.S-nitrosoglutathione prevents experimental cerebral malaria.

P2860

Q24810377-2AFA451C-DB30-40C2-A113-82FD59005298 Q26772866-FAA2D76B-77CA-44C1-BC02-48D2496F5AB5 Q27347602-10F7E09F-6E54-4677-B7B0-88CBF04FF677 Q28080030-67A931CF-5347-4DBE-BA31-A2E7B98F2FDC Q28486022-897A5316-4120-454F-8C73-7067A37096BC Q28742640-DD903FC8-9E2E-4D25-AB5F-B19AD02916BC Q30411019-797C0080-0ACE-4C2F-9375-8EFA39BF8414 Q30536657-BEB8730F-77A3-4159-A799-CBD16FC2E503 Q33622909-7EA15EC4-BEC9-405C-8C28-F87646C05CA2 Q33721892-53C6BDDE-EE02-42D3-9B1B-7F5DD4B98BB4 Q34685370-930A04E8-ABCA-4431-AA95-8B20C8EA1611 Q34974570-C8D8BA3C-59B5-47E1-AFE9-2A552EC93751 Q35101529-0C33DBA3-F497-4C39-82BD-5168D8544417 Q35113069-AA1F466C-5433-4563-8D84-21E63E95C5FB Q35150645-5FB34834-E507-496B-9423-493C5AB0F132 Q35679569-6EFF1B93-DE78-4245-BAC9-9D744043EE1F Q35806274-2A547078-D00D-4DAF-A4F3-CE0D540A060D Q35837963-754F4E82-9B92-4C5F-8481-21A2DF47E702 Q36162324-AB1FE319-8C3E-4CEC-8477-8FC6FB0B5262 Q36183209-8639073E-A4A3-41B7-B016-38798DA200CA Q36202059-F35895A2-5101-4315-ABBD-451BC6C62567 Q36209383-64BDEB84-94CF-43C6-A0CA-F30B19F2170D Q36292400-8DB78EC6-1617-43E0-AF8D-7C1039AFF76F Q36534958-1426CB51-77C5-4EB7-8132-122C32128B46 Q36785435-A21F24D1-7254-469C-930D-9E6358EF9F0A Q37098382-F08E8AFB-82D1-47C4-9103-1ED42222A4ED Q37263464-85173B75-DFDD-4BFE-95A6-B145AA3C199C Q37264802-CACDD4A0-9997-420E-937F-108C4752E224 Q37466271-BCF2F165-7AEF-4C82-884C-2B0D5A949B24 Q37532357-01F21ABF-F88F-4928-B2BF-17E4704FA98A Q37734218-B8A654B0-7018-4097-8A1E-4FCAAF989062 Q37879203-482677BB-921B-4F23-83FE-E60A59A55D94 Q37929759-328BC889-40F0-47E4-8042-3653F2F99CB0 Q37962336-71344D73-04FB-450F-A81E-29BBFD4F7935 Q38050556-316F1883-2A16-4306-A675-202443FF9472 Q38182192-82DF1D4C-AB0C-4D86-9FEF-578871D2424C Q38262285-47F9396D-9ED8-49DB-A85D-86509C2A1CE5 Q38666558-3A385388-DC7D-47A8-9372-DD6FC02387EC Q40498416-4BC5A4E7-6C68-4181-8F06-E1CBCC836CF1 Q41820775-D5F12F72-C7A2-41B1-8458-34F9992A0005

P2860

Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q34328743

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@ast

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@en

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@nl

type

label

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@ast

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@en

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@nl

prefLabel

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@ast

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@en

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@nl

P1433

Q34328743-4CB11754-C9A2-474F-BBBC-C3D9DE4A00E4

P1476

Q34328743-3D593D5E-23C9-4FE7-B5AF-817C2D9C0F97

P2093

Q34328743-6B45613D-5440-4F4F-A529-9F7476794F02

Q34328743-DA213008-EDBB-4866-9F70-09C076319732

P2860

Q34328743-00D2F6EE-6DE3-40E3-AA76-2ABFF340A6CA

Q34328743-01206933-4868-4F8D-B15A-4963A8C63A3B

Q34328743-04BF8A54-4F1F-4E33-BD11-3E71EC1284FD

Q34328743-0A3504E7-B5AE-423F-B03F-F3B7C817E4B0

Q34328743-0DA5EC4B-5D2B-4619-B828-08EDD06AE8E7

Q34328743-0E15403C-1E3E-46AE-A364-C66549B06030

Q34328743-148D1C0F-6161-42F5-99A6-9605EBD7C938

Q34328743-16F1070B-DBDE-4BC6-9060-21310962F6FE

Q34328743-170F4527-0402-4101-B89D-1FEB6FAEFA44

Q34328743-1EB730BA-5767-42E5-866E-C73A57CC090C

P304

Q34328743-F2DE42AB-7EE4-4FFF-9964-EA0DC143BC6A

P31

Q34328743-59B9917E-AA10-41C3-80F5-CFEFE96AE815

P356

Q34328743-6AE9F03F-4BF7-4D89-B6FF-4F9458A77959

P433

Q34328743-02769CC3-A035-4EFE-B4F6-5429A25D2EE2

P478

Q34328743-661CE6E9-3DF3-4DBC-8482-E30D5CBD4980

P50

Q34328743-20AAC7CA-60E7-42D4-BB69-CAAF945A5091

Q34328743-F1981A98-1A60-4652-94EC-3A80FBAA210E

P577

Q34328743-FF9910C1-7C36-4481-B99D-0D47088F154D

P5875

Q34328743-CA91CF00-946C-4305-9DB8-E74D9DEB0496

P698

Q34328743-4E8DFF97-BBF7-4BCB-B1D7-8B934C74E0DD

P921

Q34328743-02F355B5-C891-4E8C-8553-94673C0F4D41

Q34328743-569EDCD7-FDAD-434D-9088-BC262A15B661

Q34328743-8938E5D4-CC1A-41C6-8D8F-5F612EC78FF5

P932

Q34328743-43A24D59-31EA-4FAA-A683-C56D07BF52D2

P356

P1433

Expert Review of Anti-infective Therapy

P1476

Adjunctive therapy for cerebra ...... Plasmodium falciparum malaria

@en

P2093

Elizabeth Kutamba

http://www.w3.org/2001/XMLSchema#string

Keith Mugarura

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution of clinical episodes of Plasmodium falciparum malaria

Release of sequestered malaria parasites upon injection of a glycosaminoglycan

Effects of early cerebral malaria on cognitive ability in Senegalese children

Can erythropoietin be used to prevent brain damage in cerebral malaria?

Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy.

Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial.

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations.

Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review.

Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study.

P304

997-1008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERI.10.90

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46157420

http://www.w3.org/2001/XMLSchema#string

P698

20818944

http://www.w3.org/2001/XMLSchema#string

P921

cerebral malaria

Plasmodium falciparum

P932

2987235

http://www.w3.org/2001/XMLSchema#string